- Conditions
- Esophageal Carcinoma
- Interventions
- Tetrathiomolybdate (TM), Radiation, Surgery
- Drug · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2013
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 5,320
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Opioid-use Disorder, Opioid-Related Disorders
- Interventions
- Open-Label Placebo (OLP)
- Behavioral
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- LY2940680, Carboplatin, Etoposide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 12
- States / cities
- Fayetteville, Arkansas • Athens, Georgia • Las Vegas, Nevada + 8 more
- Conditions
- Congenital Adrenal Hyperplasia, Hyperplasia, Adrenal Hyperplasia, Congenital Disorders, Adrenocortical Hyperfunction, Disorders of Sex Development, Urogenital Abnormalities, Genetic Diseases, Inborn, Steroid Metabolic Diseases, Inborn, Adrenal Gland Disease, Hydrocortisone
- Interventions
- Subcutaneous hydrocortisone
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Acute Myeloid Leukemia
- Interventions
- oral azacitidine (CC-486)
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- ABC/DTG/3TC FDC, Ongoing cART regimen
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 87
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 64 more
- Conditions
- Prostatic Neoplasms
- Interventions
- 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 20
- States / cities
- Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more
- Conditions
- Healthy Participants
- Interventions
- Elecoglipron, Atorvastatin, Rosuvastatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Glendale, California • Brooklyn, Maryland
- Conditions
- Idiopathic Membranous Nephropathy
- Interventions
- Rituximab, Cyclosporine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 13 more
- Conditions
- Solid Tumor
- Interventions
- rigosertib
- Drug
- Lead sponsor
- Traws Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Refractory or Recurrent Hypermutated Malignancies, Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- The Hospital for Sick Children
- Other
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania
- Conditions
- Richter Syndrome
- Interventions
- Venetoclax, DA-EPOCH-R, R-CHOP
- Drug · Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Columbus, Ohio • Houston, Texas
- Conditions
- Breast Neoplasms, Neoplasm Metastasis
- Interventions
- Vinorelbine, Investigator's choice of treatment, afatinib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 6
- States / cities
- Bakersfield, California • Fullerton, California • Los Angeles, California + 3 more
- Conditions
- Hypertension, Hypercortisolemia, Cushing Syndrome
- Interventions
- Osilodrostat, Placebo
- Drug
- Lead sponsor
- RECORDATI GROUP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Canton, Ohio • Weslaco, Texas
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
- Interventions
- Temsirolimus, Etoposide, Cyclophosphamide, Methotrexate, Hydrocortisone, Cytarabine
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 25
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 22 more
- Conditions
- Critical Illness, Depressive Symptoms
- Interventions
- Ketamine (0.5 mg/kg), Normal Saline (0.9% NaCl)
- Drug · Other
- Lead sponsor
- Hospital Italiano de Buenos Aires
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Cancer, VTE (Venous Thromboembolism)
- Interventions
- Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Heart Failure, Systolic
- Interventions
- nicotinamide riboside, Placebo
- Dietary Supplement · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Leukemia, Aplastic Anemia, Bone Marrow Failure Syndromes, SCID
- Interventions
- PCA plus methadone (Experimental), PCA Alone (SOC)
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2028 – 2029
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
- Interventions
- Valproate, Placebo, Patch
- Drug · Behavioral
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetes
- Interventions
- PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab
- Device · Drug
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Heart Transplantation, Liver Transplantation, Kidney Transplantation
- Interventions
- FK506E
- Drug
- Lead sponsor
- Astellas Pharma Europe Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Glargine, Sitagliptin, Metformin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 35 Years to 71 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Pembrolizumab, Cisplatin, Carboplatin, Etoposide, Radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York